J&J's Zytiga Extends Life, Boosts Prostate Drug Market



Hormonal Drug Boosts Survival After Prostate Cancer's Return: Study

But, newer and possibly more effective drugs now available and being studied.

By Amy Norton, HealthDay News

Don't Miss This

Sign Up for OurMen's HealthNewsletter

Thanks for signing up!You might also like these other newsletters:

Prostate cancer usually progresses slowly, so it took more than a decade to see a survival advantage with bicalutamide.
Prostate cancer usually progresses slowly, so it took more than a decade to see a survival advantage with bicalutamide.
iStock.com (2)

When prostate cancer recurs after surgery, treatment with both radiation and a testosterone-suppressing drug can extend some men's lives, a new clinical trial finds.

In a nearly 20-year study, researchers found that the combination therapy cut the risk of death from prostate cancer in half, compared to radiation alone.

And that translated into better overall survival, the researchers reported in the Feb. 2 New England Journal of Medicine.

After 12 years, just over 76 percent of men who'd received radiation and the hormonal drug bicalutamide (Casodex) were still alive. That compared with just over 71 percent of those who'd received radiation alone.

Not all patients benefited from extra treatment, though -- including those with "lower-risk" prostate cancer that, despite recurring, appeared less aggressive.

And the testosterone-blocking drug carried expected side effects, such as enlarged breasts.

But on balance, the findings should be "practice-changing," said senior researcher Dr. William Shipley, of Massachusetts General Hospital in Boston.

RELATED: Number of Advanced Prostate Cancer Cases Soar

The trial was funded by the U.S. National Cancer Institute (NCI) and AstraZeneca, which makes Casodex.

Other prostate cancer experts said the results offer "important" information. But they also said it's unclear how the findings will affect current prostate cancer treatment.

Since this trial began in 1998, "the prostate cancer therapeutic landscape has changed," said Dr. Alexander Kutikov, an associate professor of urologic oncology at Fox Chase Cancer Center in Philadelphia.

For one, Kutikov said, bicalutamide has been largely replaced by newer hormonal medications. Known as gonadotropin-releasing hormone agonists, they include drugs such as leuprolide (Eligard, Lupron) and goserelin (Zoladex).

And the newer medications, along with radiation, are already offered to some men with recurrent prostate cancer, said Dr. Ashutosh Tewari. He's chair of urology at Mount Sinai's Icahn School of Medicine in New York City.

Other ongoing trials are looking at those therapies, researchers said. One tested the effects of adding goserelin to radiation therapy in men with early signs of prostate cancer recurrence.

So far, that study has found that the combination keeps more men progression-free over five years. And the duration of the hormone therapy was much shorter, versus the bicalutamide trial: three months, rather than two years.

Plus, Kutikov said, when today's hormonal drugs are used with radiation as an initial therapy -- not for a recurrence -- six months of hormonal treatment has "proven to be sufficient" for many men.

"As such," Kutikov said, "the study's findings will need to be reconciled with current clinical practice."

Still, the bicalutamide trial is the only one that has gone on long enough to show that adding hormonal therapy to radiation can actually extend the lives of some men with biochemical recurrences.

A biochemical recurrence means their levels of prostate-specific antigen (PSA) start to rise again -- an early sign that the cancer may be returning.

Prostate cancer usually progresses slowly, so it took more than a decade to see a survival advantage with bicalutamide, the researchers said.

According to Tewari, the study offers "proof-of-principle" that adding "something to radiation is better than radiation alone."

Roughly 181,000 U.S. men were diagnosed with prostate cancer in 2019, according to estimates from the NCI.

Because the disease is typically slow-growing, most men are diagnosed when the tumor is confined to the prostate gland, according to the NCI.

Many patients have the option of delaying treatment and going with "active surveillance" -- where doctors closely monitor the cancer for signs of progression.

But in the United States, studies show that most men choose treatment. That treatment typically involves surgery to remove the prostate. Of men who undergo surgery, more than 30 percent will have a biochemical recurrence, according to Shipley's team.

Shipley and his colleagues studied 760 men who'd undergone surgery for localized prostate cancer and later had a biochemical recurrence.

They randomly assigned the patients to take either bicalutamide or placebo pills every day for two years. All of the men underwent 6.5 weeks of radiation.

After 12 years, almost 6 percent of bicalutamide patients had died of prostate cancer, versus just over 13 percent of placebo patients.

The benefits were not uniform, though, Kutikov pointed out.

Hormonal therapy made no difference in the survival rates of men with relatively low PSA levels when they entered the trial (below 0.7). The same was true of men with "Gleason scores" below 7.

That score is based on what a tumor sample looks like under the microscope. A lower score means the cells look more "normal," and the cancer is less likely to progress.

That, Kutikov said, suggests that men with lower-risk cancer could be "overtreated" if they receive hormonal therapy.

Overtreatment is a worry because it needlessly exposes patients to the risk of side effects.

In the case of hormonal therapies in general, Kutikov said, the potential side effects include lost libido and erectile dysfunction.






Video: Dr. Chi on Abiraterone Versus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer

Hormonal Drug Boosts Survival After Prostate Cancers Return: Study
Hormonal Drug Boosts Survival After Prostate Cancers Return: Study images

2019 year
2019 year - Hormonal Drug Boosts Survival After Prostate Cancers Return: Study pictures

Hormonal Drug Boosts Survival After Prostate Cancers Return: Study advise
Hormonal Drug Boosts Survival After Prostate Cancers Return: Study forecast photo

Hormonal Drug Boosts Survival After Prostate Cancers Return: Study pictures
Hormonal Drug Boosts Survival After Prostate Cancers Return: Study pics

Hormonal Drug Boosts Survival After Prostate Cancers Return: Study Hormonal Drug Boosts Survival After Prostate Cancers Return: Study new foto
Hormonal Drug Boosts Survival After Prostate Cancers Return: Study new photo

foto Hormonal Drug Boosts Survival After Prostate Cancers Return: Study
images Hormonal Drug Boosts Survival After Prostate Cancers Return: Study

Watch Hormonal Drug Boosts Survival After Prostate Cancers Return: Study video
Watch Hormonal Drug Boosts Survival After Prostate Cancers Return: Study video

Communication on this topic: Hormonal Drug Boosts Survival After Prostate Cancers , hormonal-drug-boosts-survival-after-prostate-cancers/
Communication on this topic: Hormonal Drug Boosts Survival After Prostate Cancers , hormonal-drug-boosts-survival-after-prostate-cancers/ , hormonal-drug-boosts-survival-after-prostate-cancers/

Related News


Declining Sense of Smell Could Be the First Sign of Alzheimers Disease
Heart Health: The Best Foods for Your Heart
How to Grow Your Email List
How to Add a URL to Bing
5 Tips to Spice Up Your Valentines Day
Nalbuphine Reviews
How to Make Yerba Mate
5 Successful Women on How to Actually Have a Work-LifeBalance
7 Genius Ways To Use Up Leftover Quinoa
How to Cope With Criticism As a Leader
Keeping Mens Hormones in Balance
News: Lindsay Ellingson’s 10-Minute Pilates Workout A Weird Form ofDeodorant
How to Catch Ants
10 Reasons to Strength Train



Date: 16.12.2018, 06:38 / Views: 41281